Core Viewpoint - The announcement from Huiyu Pharmaceutical indicates that shareholder Huang Qianyi has reduced his stake in the company due to judicial enforcement actions, impacting his overall shareholding percentage and total shares held [1] Group 1: Shareholding Details - Huang Qianyi held 27,219,439 shares before the reduction, representing 6.426% of the total share capital [1] - Following the reduction, Huang Qianyi now holds 25,919,439 shares, which is 6.119% of the total share capital [1] Group 2: Reduction Specifics - The reduction occurred between February 9 and 10, 2026, through centralized bidding transactions [1] - A total of 1,300,000 shares were sold, accounting for 0.307% of the current total shares [1] - The share reduction was executed at a price range of 19.41 to 19.77 yuan per share, resulting in a total amount of 25.4803 million yuan [1] Group 3: Compliance and Plan - The share reduction was completed in accordance with relevant regulations and aligned with the previously announced reduction plan [1]

Core Viewpoint - Sichuan is focusing on high-quality development of the biopharmaceutical industry, aiming to establish itself as an innovation hub in Western China, with an emphasis on accelerating the transformation of scientific research achievements into accessible quality medicines for the public [1][3]. Group 1: Innovation and Regulatory Efficiency - The chairman of Sichuan Huiyu Pharmaceutical Co., Ding Zhao, highlighted the importance of efficient communication between enterprises and regulatory departments to expedite the approval process for new drugs [3]. - Ding proposed the establishment of a regional drug review center within the Chengdu-Chongqing economic circle to enhance the efficiency of drug approvals, which could significantly benefit local pharmaceutical companies [3]. - The establishment of the "Southwest Drug Review Center" is anticipated to be a major advantage for pharmaceutical enterprises in Sichuan and Chongqing by 2025 [3]. Group 2: Drug Pricing and Collection Policies - Ding emphasized the need to optimize drug collection policies to lower inflated drug prices, ensuring affordability for patients while maintaining the sustainability of medical insurance funds [3]. - The recent improvements in collection policies are seen as a positive development, balancing patient accessibility, insurance sustainability, and the innovation incentives for companies [3][4]. Group 3: Collaborative Innovation and Data Integration - Ding called for the government to lead efforts in integrating clinical data from research institutions and medical facilities to promote the deep integration of "artificial intelligence + medicine" [4]. - There is a push for better collaboration among research institutions, innovative pharmaceutical companies, and regulatory bodies to accelerate the transformation of innovative results into effective treatments [4]. - The expectation is that continuous policy innovation and systematic support will help Sichuan cultivate more globally competitive biopharmaceutical innovators [4].

Core Viewpoint - Huiyu Pharmaceutical is expected to report a significant decline in revenue and net profit for the year 2025, marking its first loss since its listing in 2021 [1] Group 1: Financial Performance - The company forecasts a revenue range of 960 million to 1.09 billion yuan for 2025, representing a year-on-year decline of 12.28% to 0.40% [1] - The projected net profit attributable to the parent company is expected to be a loss between 29 million and 24 million yuan, indicating a year-on-year decline of 108.91% to 107.38% [1] - Historical net profits from 2021 to 2024 were 446 million, 249 million, 140 million, and 325 million yuan respectively [1] Group 2: Reasons for Loss - The anticipated loss is primarily attributed to fair value changes resulting from the stock price fluctuations of Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which was listed on the Hong Kong Stock Exchange on August 20, 2024 [1] Group 3: Shareholder Developments - Prior to the earnings warning, the company disclosed that its second-largest shareholder, Huang Qianyi, would face judicial forced reduction of shares [1] - Huang Qianyi is the son of Huang Bingquan, one of the core founders of Huiyu Pharmaceutical [1] Group 4: Market Reaction - On January 29, the company's stock fell by 2.74%, with a total market capitalization of 8.112 billion yuan, marking a cumulative decline of over 8% over five consecutive days [2]

Core Viewpoint - The company, Huyou Pharmaceutical, anticipates a significant decline in net profit for the fiscal year 2025, projecting a loss between 29 million to 24 million yuan, which represents a year-over-year decrease of 108.91% to 107.38% [2] Financial Performance - The expected net profit attributable to the parent company for 2025 is projected to be between -29 million yuan and -24 million yuan [2] - The anticipated operating revenue for 2025 is estimated to be between 960 million yuan and 1.09 billion yuan [2]

Core Viewpoint - Huiyu Pharmaceutical (688553) is expected to report a net profit attributable to shareholders of between -24 million to -29 million yuan for 2025, representing a year-on-year decline of 107.38% to 108.91% compared to the previous year [1] Group 1: Financial Performance - The projected net profit for 2025 indicates a significant loss, with estimates ranging from -24 million to -29 million yuan [1] - This represents a drastic decline of over 100% compared to the previous year's legally disclosed data [1] Group 2: Investment Impact - The company’s investment in Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd. is set to be listed on the Hong Kong Stock Exchange on August 20, 2024, under the stock code 02410.HK [1] - Fluctuations in the stock price of the invested enterprise have led to a fair value change loss of 173 million yuan during the reporting period [1]

Group 1 - The core viewpoint of the article indicates that Huiyu Pharmaceutical expects a significant net loss for the fiscal year 2025, projecting a loss between 29 million to 24 million yuan, which represents a year-on-year decline of 108.91% to 107.38% [1] - The primary reason for this performance change is attributed to the fair value loss of 173 million yuan due to fluctuations in the stock price of its invested company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., which is set to be listed on the Hong Kong Stock Exchange on August 20, 2024, under the HKEX 18A listing standard [1]

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) has announced an expected net loss for the fiscal year 2025, projecting a loss between 24 million to 29 million yuan [1] Financial Performance - The company anticipates a net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, to be between 78 million to 93 million yuan for the fiscal year 2025 [1]

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) has disclosed an expected net loss for the fiscal year 2025, projecting a loss between 24 million to 29 million yuan for the year [1] Financial Performance - The company anticipates a net profit attributable to the parent company, excluding non-recurring gains and losses, ranging from 78 million to 93 million yuan for the fiscal year 2025 [1]

Revenue Projections - The company expects 2025 annual revenue to be between 960 million and 1.09 billion yuan, representing a year-on-year decline of 12.28% to 0.40%[4]. - The projected net loss attributable to shareholders for 2025 is estimated to be between 29 million and 24 million yuan, a year-on-year decline of 108.91% to 107.38%[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between 78 million and 93 million yuan, showing a year-on-year decline of 15.33% to a growth of 0.96%[4]. Previous Year Performance - The previous year's net profit attributable to shareholders was 325.39 million yuan, with a total profit of 349.70 million yuan[7]. - The company reported earnings per share of 0.77 yuan for the previous year[8]. Performance Change Factors - The main reason for the performance change is the fair value loss of 173 million yuan due to the stock price fluctuation of the invested company, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd.[9]. Financial Data and Audit - The financial data in the performance forecast has not been audited by a registered accountant and is based on preliminary calculations by the finance department[5]. - The company has not identified any significant uncertainties that could affect the accuracy of the performance forecast as of the announcement date[10]. - The final and accurate financial data will be disclosed in the audited annual report for 2025[11]. Investment Risks - Investors are advised to pay attention to investment risks due to the potential significant impact of stock price fluctuations on the company's financial statements[11].

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) expects a net loss attributable to shareholders of the parent company for the fiscal year 2025, ranging from a loss of 29 million yuan to a loss of 24 million yuan, representing a year-on-year decline of 108.91% to 107.38% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be between 78 million yuan and 93 million yuan for 2025, which indicates a year-on-year change of a decline of 15.33% to an increase of 0.96% compared to the previous year [1] Investment Impact - The company's invested enterprise, Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd., is set to be listed on the Hong Kong Stock Exchange under the 18A listing standard on August 20, 2024, with the stock code 02410.HK [1] - The fair value change loss of 173 million yuan during the reporting period was influenced by the stock price fluctuations of the invested enterprise [1]